Treatment of hepatocellular carcinoma

Digestive Diseases

Volumn 32, Issue 5, 2014, Pages 554-563

  Liccioni, Alexandre ^a   Reig, Maria ^a   Bruix, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Barcelona Clinic Liver Cancer; Hepatocellular carcinoma; Prognosis; Staging systems

Indexed keywords

ANTIANDROGEN; BRIVANIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; LINIFANIB; MICROSPHERE; NOLATREXED; OXALIPLATIN; RECOMBINANT INTERFERON; SEOCALCITOL; SORAFENIB; SUNITINIB; TAMOXIFEN; YTTRIUM 90; INTERFERON;

ADVANCED CANCER; ARTICLE; BARCELONA CLINIC LIVER CANCER STAGING SYSTEM; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; EARLY DIAGNOSIS; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; MICROWAVE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PHYSICAL PERFORMANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; TREATMENT PLANNING; ANIMAL; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); EVIDENCE BASED PRACTICE; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; TUMOR ABLATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS;

EID: 84904638512     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000360501     Document Type: Article

References (103)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics. CA Cancer J Clin 2013; 63: 11-30.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
4. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. American Association for the Study of Liver Diseases, July 2010. Retrieved October 4, 2010, from http:// www.aasld.org/practiceguidelines.
5. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, et al: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH), 2010 updated version. Dig Dis 2011; 29: 339-364.
6. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
7. Verslype C, Rosmorduc O, Rougier P: Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23:vii41- vii48.
8. United Network for Organ Sharing Website: Organ distribution: allocation of livers-liver transplant candidates with hepatocellular carcinoma. Revised January 2013. http://optn. transplant.hrsa.gov/PoliciesandBylaws2/policies/ pdfs/policy-8.pdf.
9. Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, de Lope CR, Reig M, et al: Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010; 51: 2020-2029.
10. Chen LD, Xu HX, Xie XY, Xie XH, Xu ZF, Liu GJ, Wang Z, et al: Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 2010; 20: 743-753.
11. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP: Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population- based study of US veterans. Hepatology 2009; 49: 116-123.
12. Patel T: Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol 2011; 8: 189-200.
13. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, et al: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104.
14. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, Massironi S, et al: The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-644.
15. Khalili KT, Kim TK, Jang HJ, Haider MA, Khan L, Guindi M, Sherman M: Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-728.
16. Sherman M: Alpha-fetoprotein: an obituary. J Hepatol 2001; 34: 603-605.
17. Ishikawa K, Sasaki A, Haraguchi N, Yoshikawa Y, Mori M: A case of an ?-fetoproteinproducing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin. Oncologist 2007; 12: 320-324.
18. Forner A, Reig M, Bruix J: Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology 2009; 137: 26-29.
19. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755.
20. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, et al: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405.
21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
22. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer; in Macleod CM (ed): Evaluation of Chemotherapeutic Agents. Columbia, Columbia University Press, 1949.
23. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
24. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
25. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C: A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-1283.
26. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, et al: Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.
27. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, et al: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207.
28. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, et al: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 2006; 131: 461-469.
29. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, Pompili M, et al: Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-108.
30. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035.
31. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, Vicaut E, et al: Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50: 1475-1483.
32. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, et al: A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010; 53: 108-117.
33. Llovet JM, Pena CEA, Lathia CD, Shan M, Meinhardt G, Bruix J; Group SIS: Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-2300.
34. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
35. D'Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231.
36. Kamath PS, Kim WR: The Model for End- Stage Liver Disease (MELD). Hepatology 2007; 45: 797-805.
37. Rodriguez de Lope C, Tremosini S, Forner A, Reig M, Bruix J: Management of HCC. J Hepatol 2012; 56(suppl):S75-S87.
38. Forner A, Reig ME, Rodriguez de Lope C, Bruix J: Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
39. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK: Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010; 52: 380-388.
40. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M: Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: metaanalysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-524.
41. Cho YK, Kim JK, Kim MY, Rhim H, Han JK: Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-459.
42. Lencioni R: Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773.
43. Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-1440.
44. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, et al: Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908- 1916.
45. Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, Abraldes JG, et al: Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012; 56: 103-108.
46. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, Festi D, et al: Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012; 256: 706-712; discussion 712-703.
47. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M: Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 2011; 17(suppl 2):S72-S80.
48. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, et al: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569-577.
49. Burrel M, Reig M, Forner A, Barrufet M, Lope CR, Tremosini S, Ayuso C, et al: Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using DC beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-1335.
50. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, Marinis A, et al: Chemoembolization with doxorubicineluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119-1128.
51. Sala M, Varela M, Bruix J: Selection of candidates with HCC for transplantation in the MELD era. Liver Transpl 2004; 10:S4-S9.
52. Varela M, Reig M, de la Mata M, Matilla A, Bustamante J, Pascual S, Turnes J, et al: Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers (in Spanish). Med Clin (Barc) 2010; 134: 569-576.
53. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
54. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, et al: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859.
55. Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M, Pons F, et al: High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004; 10: 1294-1300.
56. Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J: Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention- to-treat analysis. Hepatology 2012; 55: 132-140.
57. Lim C, Farges O: Portal vein occlusion before major hepatectomy in patients with colorectal liver metastases: rationale, indications, technical aspects, complications and outcome. J Visc Surg 149:e86-e96.
58. Van Lienden KP, van den Esschert JW, de Graaf W, Bipat S, Lameris JS, van Gulik TM, van Delden OM: Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 2013; 36: 25-34.
59. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, Denys A, et al: Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237: 208-217.
60. Lim C, Cauchy F, Azoulay D, Farges O, Ronot M, Pocard M: Tumour progression and liver regeneration - insights from animal models. Nat Rev Gastroenterol Hepatol 2013; 10: 452- 462.
61. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
62. Bismuth H, Majno PE, Adam R: Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 311-322.
63. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, Settmacher U, et al: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-1086.
64. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, et al: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
65. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group: Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13:e11-e22.
66. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, et al: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
67. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, et al: Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22- year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-509.
68. Volk ML, Vijan S, Marrero JA: A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008; 8: 839-846.
69. Cho YK, Kim JK, Kim WT, Chung JW: Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010; 51: 1284-1290.
70. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
71. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
72. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, et al: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481.
73. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, et al: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497- 507.e2.
74. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, et al: Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology 2011; 54: 868-878.
75. Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, Heusner T, et al: Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-1749.
76. Salem R, Mazzaferro V, Sangro B: Yttrium-90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges and clinical perspectives. Hepatology 2013; 58: 2188-2197.
77. Beaugrand M, Sala M, Degos F, Sherman M, Bolondi L, Evans T, Trinchet J, et al: Treatment of advanced hepatocellular carcinoma by seocalcitol (a vitamin D analogue): an international randomized double-blind placebo- controlled study in 747 patients. J Hepatol 2005; 42: 17A.
78. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, et al: Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013;31:3501-3508.
79. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, et al: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007;25:3069-3075.
80. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
81. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilana R, et al: Treatment of hepatocellular carcinoma with tamoxifen: a doubleblind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-922.
82. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, et al: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58.
83. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE: Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45: 9-15.
84. Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, Yamamoto K, et al: Effect of vitamin K 2 on the recurrence of hepatocellular carcinoma. Hepatology 2011; 54: 532- 540.
85. Ishizuka M, Kubota K, Shimoda M, Kita J, Kato M, Park KH, Shiraki T: Effect of menatetrenone, a vitamin K 2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. Anticancer Res 2012; 32: 5415-5420.
86. Riaz IB, Riaz H, Riaz T, Rahman S, Amir M, Badshah MB, Kazi AN: Role of vitamin K 2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a metaanalysis of randomized controlled trials. BMC Gastroenterol 12: 170.
87. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, Nishiguchi S: Role of vitamin K 2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358-361.
88. Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322.
89. Hanahan D, Weinberg A: Hallmarks of cancer: the next generation. Cell 2011; 144: 646- 674.
90. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, et al: Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010; 44: 239- 245.
91. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, et al: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
92. Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, et al: Diagnosis and treatment of hepatocellular carcinoma (in Spanish). Med Clin (Barc) 2009; 132: 272- 287.
93. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
94. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
95. Reig M, Rimola J, Torres F, Darnell A, Lope CR, Forner A, Llarch N, et al: Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Hepatology 2013; 58: 2023- 2031.
96. Reig M, Rodriguez de Lope C, Llarch N, Forner A, Torres F, Rios J, et al: Dermatologic adverse events within the first 60 days of sorafenib treatment are associated with better overall survival in patients with hepatocellular carcinoma. J Hepatol 2014, in press.
97. Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S, Omata M, et al: Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29:abstract 4000.
98. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, et al: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517-3524.
99. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, et al: Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2013;31(suppl 4):249.
100. Zhu AX, Rosmorduc O, Evans J, Ross P, Santoro A, Carrilho FJ, Leberre M, et al: SEARCH: a phase III, randomized, doubleblind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol 2012;23 (suppl 9):LBA2.
101. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, et al: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2012;31:3509-3516.
102. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RTP, et al: EVOLVE-1: phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J Clin Oncol 2014;32(suppl 3): 172.
103. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, et al: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067-4075.